Sentiment soured in May when Sanofi reported the failure of a phase 3 trial of its Regeneron-partnered IL-33 drug candidate ...

Medication nonadherence to oral anticoagulants and oral anti–prostate cancer medication has been scrutinized through new research conducted among patients and health care providers and presented ...

Worldwide, countries need to recruit another 44 million primary and secondary teachers by 2030 to meet demand, a new report ...

Regeneron’s cemdisiran for AChR-antibody positive and argenx’s efgartigimod for AChR-antibody negative generalized myasthenia ...

Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful ...

In OASIS 4, a Phase III study conducted outside of the US, the investigational compound elinzanetant met all primary endpoints demonstrating a statistically significant reduction in frequency of ...

Merck's Coralreef Lipids trial showed enlicitide cut LDL-C and other lipid markers, while pooled Verquvo data hinted at heart ...